BetterLife Pharma
Preclinical1 active candidate
same indication: Major Depressive Disorder (MDD)Preclinical peersame regulator: US FDAsimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
Lead program: Preclinical
Categories
1 domain / 2 areas / 1 specialization
Marvel BiosciencesTSXV: MRVL
Data updated
1 Drug Candidate
Marvel Biosciences is a Calgary-based clinical-stage biotechnology company pursuing a 'drug redevelopment' strategy to create synthetic derivatives of approved drugs with improved therapeutic profiles. Its lead candidate MB-204, a fluorinated derivative of the adenosine A2a receptor antagonist Istradefylline, is advancing through IND-enabling pre-clinical studies targeting autism spectrum disorder, Rett syndrome, and depression, with Phase 1 trials expected to begin in Australia.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Preclinical
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Sourced update
Mar 30, 2026 - Press release - BioSpace - MB-204 (Fluorinated Istradefylline Derivative) / MB-204 Programme (Rett Syndrome / Fragile X) — Phase 1 imminent
Next known catalyst
No next milestone forecast yet.
6 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
1MB-204 (Fluorinated Istradefylline Derivative)
Preclinical
Rett syndrome / Fragile X syndrome / ASD / depression
Programme Tracker
Autism Spectrum Disorder (ASD)
Primary: US (FDA)
Pre-clinicalActive
MB-204 is moving toward Phase 1: Marvel selected Novotech as CRO in March 2026 after cGMP synthesis and GLP toxicology, while continuing Rett and Fragile X preclinical positioning.
Milestones
preclinical-data
CompletedActual: Aug 1, 2023
Completed final FDA-required toxicology study for Phase 1 readiness
Why it matters: GLP tox completion means MB-204 has a complete preclinical safety package for IND filing. MB-204 is a fluorinated derivative of istradefylline (an adenosine A2A receptor antagonist already FDA-approved for Parkinson's disease as Nourianz). This is NOT a psychedelic/serotonergic compound — it works through adenosine receptor modulation.
Company milestone
CompletedActual: Mar 17, 2025
Announced plan to file FDA Orphan Drug Designation for MB-204 in Rett syndrome; preclinical data showed MB-204 outperformed Trofinetide (Daybue, the only FDA-approved Rett treatment)
Why it matters: Rett syndrome is a devastating rare neurodevelopmental disorder with only one approved treatment (Trofinetide/Daybue, which has significant GI side effects and modest efficacy). If MB-204 outperforms Trofinetide preclinically, ODD would provide 7-year market exclusivity, tax credits, and expedited review.
Company milestone
CompletedActual: Feb 3, 2026
Japanese Patent No. 2022-554855 granted for MB-204 composition of matter
Why it matters: Third major jurisdiction (after China and US) with composition of matter patent protection. Strong global IP position for MB-204.
Company milestone
CompletedActual: Mar 1, 2026
US Patent No. 12,570,656 B2 granted for MB-204 composition of matter
Why it matters: US composition of matter patent is the most commercially valuable IP protection. Completes the major-market patent trifecta (US, Japan, China).
Trial start
In progressActual: Mar 25, 2026
Selected Novotech (Australia) as CRO for Phase 1 clinical trial of MB-204
Why it matters: CRO selection is the final step before Phase 1 initiation. Australia chosen for >40% R&D tax credits under the CTN scheme. Phase 1 expected to start in 2026.
Funding milestone
CompletedActual: Mar 30, 2026
Secured $600K non-dilutive Alberta Innovates AICE grant for Phase 1 + NRC IRAP grant for liquid formulation development
Why it matters: Non-dilutive government grants fund Phase 1 and formulation work. Marvel trades on TSXV as MRVL. CEO/CSO is Dr Mark Williams.
Watch next: Phase 1 first patient dosed in Australia; ODD filing with FDA; Rett syndrome Phase 2 design
Recorded Events
Mar 30, 2026: Funding milestone
Mar 25, 2026: Trial start
Mar 1, 2026: Company milestone
Feb 3, 2026: Company milestone
Mar 17, 2025: Company milestone
Evidence Links
Marvel Biosciences Selects Novotech as CRO for Phase 1 MB-204 Trial
Press release - GlobeNewswire / Marvel Biosciences - Mar 25, 2026 - Verified
Marvel says MB-204 completed cGMP synthesis and 4-week GLP toxicology and selected Novotech as CRO for Phase 1.
Marvel Biosciences Technology - MB-204
company-website - Marvel Biosciences - May 7, 2022 - Verified
Company technology page describes MB-204 preclinical work in Rett and Fragile X syndrome models.
Rett Syndrome Research and Clinical Pipeline - MB-204
patient-advocacy-pipeline - International Rett Syndrome Foundation - Nov 26, 2024 - Verified
Pipeline page summarizes Marvel MB-204 Rett syndrome mouse-study updates and development status.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
CaaMTech
Preclinical1 active candidate
same indication: Major Depressive Disorder (MDD)Preclinical peersame regulator: US FDAsimilar active pipeline size
Enveric Biosciences
Preclinical1 active candidate
same indication: Major Depressive Disorder (MDD)Preclinical peersame regulator: US FDAsimilar active pipeline size
Red Light Holland
Preclinical1 active candidate
same indication: Major Depressive Disorder (MDD)Preclinical peersame regulator: US FDAsimilar active pipeline size
Quick Facts
- Type
- Public Biotech
- Ticker
- TSXV: MRVL
- Lead Stage
- Preclinical
- Website
- Visit